Accueil   Diary - News   All news Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial with LiquiTime® Guaifenesin

Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial with LiquiTime® Guaifenesin

Flamel Technologies announced the results of a First-in-Man (FIM) clinical study in healthy volunteers using its proprietary LiquiTime® drug delivery platform applied to guaifenesin, a broadly used expectorant. LiquiTime is designed to provide a controlled, extended release of oral liquids principally for pediatric and geriatric patients.

Read the press release